Replies to post #54406 on NorthWest Biotherapeutics Inc (NWBO)

[koman]

How about this quiz:

1) What percentage of nGBM patients randomized into the main trial are psPD (this includes radionecrosis)?
a) 10%
b) 15%
c) 20%
d) 30%

2) How will these psPD patients affect the medPFS?
a) lower it
b) raise it
c) do neither

3) Did Dr. Bosch's statement that pseudoprogression is wreaking havoc on trials refer to this p3 dcvax-L trial?
a) Yes
b) No

4) Did the pI trial results for medPFS showing 24mth reflect a correction for psPD that will NOT be utilized in this p3 trial?
a) Yes
b) NO

5) Will Baseline 1 MRI be able to capture enough psPD patients to meet the 32 enrollment number for the psPD randomized arm?
a) Yes
b) NO

[Evaluate]

1. Was Dr. Bosch positively or negatively surprised by the survival performance for rapid progressors in the information group? Positively
Bonus question: Why was he surprised? skip Do Not Know

2. If Dr. Bosch was positively surprised, what factor did he propose was responsible for better than expected results within the rapid progressor group? b .... Dosing frequency increase

a. Time
b. Dosing frequency increase.
c. Trickery
d. Other

3. What group(s) within the main trial will theoretically receive more frequent DCVax-L dosing than any other group(s) inside or outside the trial?
Those from the treatment group that crossover

4. What is novel about this additional dosing? a .... DCVax-L is increased not withdrawn when progression occurs.

a. DCVax-L is increased not withdrawn when progression occurs.
b. The controlled group is also allowed to cross over.
c. Salt
d. Pork

[Doc logic]

All your answers are correct lol.